International Extranodal Lymphoma Study Group (ielsg)

This phase 2 trial tests a combination of two drugs, ibrutinib and rituximab, in people with untreated marginal zone lymphoma (a slow-growing blood cancer). About 175 participants will receive the treatment to see if it improves complete response rates at 12 months and progressio…

This study tests a combination of two drugs, acalabrutinib and tafasitamab, in about 26 people with marginal zone lymphoma that has come back after prior treatment. The goal is to see how well the drugs shrink tumors and to check for side effects. Participants receive treatment f…

This study tests a combination of the drug pembrolizumab and standard radiation therapy for people with a rare type of lymphoma (NK/T-cell) that has not spread widely and who cannot receive chemotherapy. About 30 participants will receive radiation plus pembrolizumab every 3 week…

This study tested a combination of two drugs, chlorambucil (a chemotherapy pill) and rituximab (an antibody given as a shot under the skin), followed by maintenance rituximab, in 112 people with MALT lymphoma, a slow-growing cancer of the lymph system. The goal was to see how man…

This study looks at people with a type of lymphoma (PMLBCL) who finished standard chemo-immunotherapy and had a PET/CT scan showing no active tumor. Half will get radiation therapy as usual, and half will just be watched closely. The goal is to see if careful observation works ju…

This study tests whether adding zanubrutinib to standard rituximab works better than rituximab alone for people with a rare lymphoma of the spleen (SMZL) who haven't had treatment yet. About 122 participants will receive either the combo or rituximab alone for up to 2 years, with…

This study looks back at nearly 500 people with marginal zone lymphoma to see how well PET scans work for staging the disease and predicting how patients will do. Researchers will compare PET results with CT scans and other tests to see if PET provides extra useful information. T…